Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: A post-hoc analysis of the KRN1493 study

Therapeutic Apheresis and Dialysis

Volumn 12, Issue SUPPL. 1, 2008, Pages

  Komaba, Hirotaka ^a   Fukagawa, Masafumi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcimimetics; Cinacalcet; JSDT guidelines; PTH; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

CALCIUM BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEMODIALYSIS PATIENT; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MORBIDITY; MORTALITY; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

CALCIUM; GUIDELINES AS TOPIC; HUMANS; HYPERPARATHYROIDISM, SECONDARY; JAPAN; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; SOCIETIES, MEDICAL;

EID: 54949120981     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00631.x     Document Type: Conference Paper

References (39)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999 56 (Suppl. 73 S14 S19.
2. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000 11 : 1141 52.
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 342 : 1478 83.
4. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 15 : 2208 18.
5. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006 70 : 771 80.
6. Nakai S, Akiba T, Kazama JJ et al. Effects of serum levels of calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008 12 : 49 54.
7. Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial (in press).
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 (Suppl. 3 S1 S201.
9. Kimata N, Miwa N, Otsubo S et al. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese University center result. Ther Apher Dial 2007 11 (Suppl. 1 S62 S66.
10. Komaba H, Igaki N, Takashima M et al. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial 2008 12 : 42 8.
11. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998 95 : 4040 5.
12. Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 1999 10 : 97 103.
13. Goodman WG, Frazao JM. Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000 58 : 436 45.
14. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002 13 : 1017 24.
15. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003 14 : 575 83.
16. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 350 : 1516 25.
17. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005 16 : 800 7.
18. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005 67 : 760 71.
19. Arenas M, Alvarez-Ude F, Gill M et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007 22 : 1639 44.
20. Messa P, Macário F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008 3 : 36 45.
21. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005 68 : 1793 800.
22. Fukagawa M, Yumita S, Akizawa T et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008 23 : 328 35.
23. Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2008 12 : 117 25.
24. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005 20 : 2186 93.
25. 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001 37 : 532 43.
26. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007 2 : 898 905.
27. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993 92 : 1436 43.
28. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996 81 : 1598 606.
29. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006 70 : S3 S7.
30. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997 13 : 78 86.
31. Tominaga Y, Matsuoka S, Sato T et al. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy. Ther Apher Dial 2007 11 : 269 76.
32. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005 90 : 135 41.
33. Eriguchi R, Umakoshi J, Tominaga Y, Sato Y. Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl. NDT Plus 2008 1 : 218 20.
34. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006 1 : 323 6.
35. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007 22 : 577 83.
36. Garside R, Pitt M, Anderson R, Mealing S, D'Souza R, Stein K. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007 22 : 1428 36.
37. Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD. A cost utility analysis. Am J Kidney Dis 2007 49 : 801 13.
38. Nakai S, Masakane I, Akiba T et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial 2007 11 : 411 41.
39. Jean G, Chazot C, Charra B. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Nephrol Dial Transplant 2007 22 : 2102 3.